Anavex Life Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Anavex Life Sciences wird ein Gewinn- und Umsatzwachstum von 47.7% bzw. 52.4% pro Jahr prognostiziert, während der Gewinn pro Aktie um 52.3% pro Jahr wachsen soll.

Wichtige Informationen

47.7%

Wachstumsrate der Gewinne

52.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	52.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	04 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease

Nov 11

Anavex: Understanding Their Latest Alzheimer's Data News With Caution

Nov 05

Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)

Oct 08

Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising

Jul 29

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Jul 17

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Apr 01

Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Sep 19

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

May 10

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

Jan 16

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Oct 01

Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia

Sep 19

Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease

Sep 07

Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01

Aug 09

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Jun 17

Anavex: Increasing Shareholder Value Against All Odds

May 31

Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease

Mar 23

We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn

Mar 03

Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease

Feb 09

Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity

Feb 02

Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers

Jun 21

Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease

Jun 14

Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment

Jun 08

Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease

Apr 28

Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Apr 16

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:AVXL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2027	630	402	822	610	2
9/30/2026	390	481	542	738	2
9/30/2025	N/A	80	-60	222	3
9/30/2024	N/A	-46	-58	-39	3
6/30/2024	N/A	-42	-30	-30	N/A
3/31/2024	N/A	-41	-32	-32	N/A
12/31/2023	N/A	-43	-29	-29	N/A
9/30/2023	N/A	-48	-28	-28	N/A
6/30/2023	N/A	-52	-26	-26	N/A
3/31/2023	N/A	-53	-25	-25	N/A
12/31/2022	N/A	-50	-27	-27	N/A
9/30/2022	N/A	-48	-24	-24	N/A
6/30/2022	N/A	-45	-28	-28	N/A
3/31/2022	N/A	-43	-28	-28	N/A
12/31/2021	N/A	-41	-26	-26	N/A
9/30/2021	N/A	-38	-30	-30	N/A
6/30/2021	N/A	-32	-29	-29	N/A
3/31/2021	N/A	-28	-25	-25	N/A
12/31/2020	N/A	-28	-23	-23	N/A
9/30/2020	N/A	-26	-21	-21	N/A
6/30/2020	N/A	-26	-18	-18	N/A
3/31/2020	N/A	-26	-21	-21	N/A
12/31/2019	N/A	-26	-20	-20	N/A
9/30/2019	N/A	-26	-19	-19	N/A
6/30/2019	N/A	-26	-20	-20	N/A
3/31/2019	N/A	-23	-15	-15	N/A
12/31/2018	N/A	-20	-13	-13	N/A
9/30/2018	N/A	-17	-13	-13	N/A
6/30/2018	N/A	-17	-11	-11	N/A
3/31/2018	N/A	-18	N/A	-12	N/A
12/31/2017	N/A	-14	N/A	-9	N/A
9/30/2017	N/A	-13	N/A	-9	N/A
6/30/2017	N/A	-15	N/A	-9	N/A
3/31/2017	N/A	-13	N/A	-8	N/A
12/31/2016	N/A	-14	N/A	-9	N/A
9/30/2016	N/A	-15	N/A	-9	N/A
6/30/2016	N/A	-14	N/A	-9	N/A
3/31/2016	N/A	-16	N/A	-8	N/A
12/31/2015	N/A	-15	N/A	-7	N/A
9/30/2015	N/A	-12	N/A	-4	N/A
6/30/2015	N/A	-15	N/A	-4	N/A
3/31/2015	N/A	-12	N/A	-3	N/A
12/31/2014	N/A	-11	N/A	-3	N/A
9/30/2014	N/A	-10	N/A	-3	N/A
6/30/2014	N/A	-5	N/A	-2	N/A
3/31/2014	N/A	-4	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AVXL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.6%).

Ertrag vs. Markt: AVXL wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: AVXL wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: AVXL wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: AVXL wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von AVXL in 3 Jahren voraussichtlich hoch sein wird

Anavex Life Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast breakeven date moved forward to 2025

Price target decreased by 26% to US$40.00

Forecast to breakeven in 2025

Price target increased by 19% to US$47.00

Price target increased by 30% to US$41.67

Price target decreased to US$33.25

Recent updates

Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease

Anavex: Understanding Their Latest Alzheimer's Data News With Caution

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

Anavex Life Sciences Corp Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)

Anavex Life Sciences Corp. to Report Q3, 2024 Results on Aug 06, 2024

New minor risk - Share price stability

Forecast breakeven date moved forward to 2025

Anavex Life Sciences Corp. Presents comprehensive results from the Phase IIb/III study of Blarcamesine at Alzheimer's Association Conference

Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Insufficient new directors

Anavex Life Sciences Corp Announces Management Appointments

Anavex Life Sciences Corp., Annual General Meeting, Jun 18, 2024

Anavex Life Sciences Corp. to Report Q2, 2024 Results on May 09, 2024

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

President notifies of intention to sell stock

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®?3-71 in Schizophrenia

Levi & Korsinsky, LLP Files Complaint Against Anavex Life Sciences Corporation

Levi & Korsinsky, LLP Files Complaint Against Anavex Life Sciences Corporation

Anavex Life Sciences Corp. to Report Q1, 2024 Results on Feb 07, 2024

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia

Price target decreased by 26% to US$40.00

Anavex Life Sciences Corp. Announces First Entire Clinical Gene Pathway Data of Anavex®2-73 from Avatar Study in Patients with Rett Syndrome

Anavex Life Sciences Corp. Receives Agreement from the Committee for Medicinal Products for Human Use for the Submission of A Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease

New major risk - Revenue and earnings growth

Anavex Life Sciences Corp. to Report Fiscal Year 2023 Results on Nov 27, 2023

Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency

Anavex Life Sciences Corp. Appoints David Goldberger as Senior Vice President Regulatory Affairs

Anavex Life Sciences Corp. Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX(R) 3-71 to Prevent Cognitive Decline in Alzheimer's Disease

New major risk - Revenue and earnings growth

Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Anavex Life Sciences Corp. Announces Phase 2b/3 Trial of Blarcamesine (ANAVEX 2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration

Anavex Life Sciences Reports Publication of ANAVEX®?3-71 in Clinical Journal Confirming ANAVEX®? 3-71 Clinical Cardiovascular Safety

Anavex Life Sciences Corp. to Report Q3, 2023 Results on Aug 08, 2023

Chairman notifies of intention to sell stock

Anavex Life Sciences Corp. Announces Long-Term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX(R)2-73 (blarcamesine) for Rett Syndrome

Anavex Life Sciences Corp.'s ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome

Anavex Life Sciences Corp. Announces Completion of Anavex((R))2-73 (Blarcamesine) Excellence Phase 2/3 Rett Syndrome Clinical Trial

Forecast to breakeven in 2025

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

Price target increased by 19% to US$47.00

Anavex Life Sciences Corp. Announces Exceeding of Enrollment Target for the ANAVEX(R)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

Anavex Life Sciences Corp. to Report Q1, 2023 Results on Feb 07, 2023

Price target increased by 30% to US$41.67

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

Anavex Life Sciences Corp. Announces the Appointment of Timo Grimmer, Md, to Its Scientific Advisory Board

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

Anavex Life Sciences Corp. to Report Q4, 2022 Results on Nov 28, 2022

Price target decreased to US$33.25

Insufficient new directors

Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2B/3 Data of Oral Anavex®2-73 (Blarcamesine) for Early Alzheimer’s Disease At the Upcoming Clinical Trials on Alzheimer’S Disease (Ctad) Congress 2022

Forecast to breakeven in 2025

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia

Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease

Anavex Life Sciences Corp. Reports New Publication in Medical Journal Highlighting the Relevance of Sigmar1 Activation to Compensate for Early Alzheimer's Disease

Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01

Anavex Life Sciences Corp. to Report Q3, 2022 Results on Aug 09, 2022

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Anavex: Increasing Shareholder Value Against All Odds

Independent Director exercised options and sold US$407k worth of stock

Anavex Life Sciences Corp. to Report Q2, 2022 Results on May 10, 2022

Price target decreased to US$31.00

Insufficient new directors

Anavex Life Sciences Corp., Annual General Meeting, May 24, 2022

Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease

We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn

Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease